亚洲碳青霉烯耐药的患病率和分子流行病学:系统回顾和荟萃分析。

IF 6.3 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Nishadi Jayathilaka, Sashini Shehana, Dilini Nakkawita, Thamarasi Senaratne
{"title":"亚洲碳青霉烯耐药的患病率和分子流行病学:系统回顾和荟萃分析。","authors":"Nishadi Jayathilaka, Sashini Shehana, Dilini Nakkawita, Thamarasi Senaratne","doi":"10.1186/s13643-025-02776-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Carbapenems are a group of last-resort antibiotics used to treat serious life-threatening infections. The emergence of resistance to carbapenems is a major public health threat. However, comprehensive information on the prevalence and molecular epidemiology of carbapenem resistance (CR) among Asian countries is lacking. Therefore, we aimed to determine the prevalence of CR and associated molecular determinants quantitatively among Asian countries.</p><p><strong>Methods: </strong>In this systematic review and meta-analysis, we searched published reports in electronic databases such as PubMed, ScienceDirect, the Cochrane Library, and Web of Science from 1<sup>st</sup> of January 2014 to 31<sup>st</sup> of January 2024 that fulfilled these criteria; original studies conducted in Asian countries including clinical isolates, and published in English. Data extraction and risk-of-bias assessment were performed by two independent reviewers. The pooled prevalence of CR with 95% confidence interval (CI) was computed with a random effects model. Heterogeneity across studies was determined by I<sup>2</sup>. The geographical location, income level, publication year, and sample size were analyzed as subgroups.</p><p><strong>Results: </strong>We identified 2518 eligible studies, of which 37 assessed the CR prevalence data of 10,433 patients. The pooled prevalence (PPr) of CR was 31.3% (95% CI: 0.22 to 0.40; I<sup>2</sup> = 99.9%; P = 0.00). A trend of CR incidence was observed from 2004 to 2023, with PPr values ranging from 7.4% to 50.6%. A variation in the distribution of CR genes was observed, with bla<sub>NDM</sub> being the most common gene, followed by bla<sub>OXA</sub> and bla<sub>KPC</sub>. Univariate meta-regression analysis indicated that geographical location, income level, publication year, and sample size did not significantly affect heterogeneity (P < 0.05).</p><p><strong>Conclusion: </strong>The results suggest that surveillance of CR among Asian countries is essential to reduce the burden of antibiotic resistance. Mitigating the impact of CR infections will safeguard the efficacy of carbapenems for future generations and reduce further dissemination of CR genes.</p><p><strong>Systematic review registration: </strong>PROSPERO CRD42024515806.</p>","PeriodicalId":22162,"journal":{"name":"Systematic Reviews","volume":"14 1","pages":"123"},"PeriodicalIF":6.3000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12139192/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prevalence and molecular epidemiology of carbapenem resistance in Asia: a systematic review and meta-analysis.\",\"authors\":\"Nishadi Jayathilaka, Sashini Shehana, Dilini Nakkawita, Thamarasi Senaratne\",\"doi\":\"10.1186/s13643-025-02776-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Carbapenems are a group of last-resort antibiotics used to treat serious life-threatening infections. The emergence of resistance to carbapenems is a major public health threat. However, comprehensive information on the prevalence and molecular epidemiology of carbapenem resistance (CR) among Asian countries is lacking. Therefore, we aimed to determine the prevalence of CR and associated molecular determinants quantitatively among Asian countries.</p><p><strong>Methods: </strong>In this systematic review and meta-analysis, we searched published reports in electronic databases such as PubMed, ScienceDirect, the Cochrane Library, and Web of Science from 1<sup>st</sup> of January 2014 to 31<sup>st</sup> of January 2024 that fulfilled these criteria; original studies conducted in Asian countries including clinical isolates, and published in English. Data extraction and risk-of-bias assessment were performed by two independent reviewers. The pooled prevalence of CR with 95% confidence interval (CI) was computed with a random effects model. Heterogeneity across studies was determined by I<sup>2</sup>. The geographical location, income level, publication year, and sample size were analyzed as subgroups.</p><p><strong>Results: </strong>We identified 2518 eligible studies, of which 37 assessed the CR prevalence data of 10,433 patients. The pooled prevalence (PPr) of CR was 31.3% (95% CI: 0.22 to 0.40; I<sup>2</sup> = 99.9%; P = 0.00). A trend of CR incidence was observed from 2004 to 2023, with PPr values ranging from 7.4% to 50.6%. A variation in the distribution of CR genes was observed, with bla<sub>NDM</sub> being the most common gene, followed by bla<sub>OXA</sub> and bla<sub>KPC</sub>. Univariate meta-regression analysis indicated that geographical location, income level, publication year, and sample size did not significantly affect heterogeneity (P < 0.05).</p><p><strong>Conclusion: </strong>The results suggest that surveillance of CR among Asian countries is essential to reduce the burden of antibiotic resistance. Mitigating the impact of CR infections will safeguard the efficacy of carbapenems for future generations and reduce further dissemination of CR genes.</p><p><strong>Systematic review registration: </strong>PROSPERO CRD42024515806.</p>\",\"PeriodicalId\":22162,\"journal\":{\"name\":\"Systematic Reviews\",\"volume\":\"14 1\",\"pages\":\"123\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2025-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12139192/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Systematic Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13643-025-02776-5\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Systematic Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13643-025-02776-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:碳青霉烯类抗生素是一组用于治疗严重危及生命的感染的最后手段。碳青霉烯类耐药性的出现是一个重大的公共卫生威胁。然而,关于亚洲国家碳青霉烯耐药(CR)的流行和分子流行病学的全面信息是缺乏的。因此,我们旨在定量确定亚洲国家CR患病率和相关分子决定因素。方法:在本系统评价和荟萃分析中,我们检索了2014年1月1日至2024年1月31日在PubMed、ScienceDirect、Cochrane Library和Web of Science等电子数据库中发表的符合这些标准的报告;在亚洲国家进行的原始研究,包括临床分离,并以英文发表。数据提取和偏倚风险评估由两名独立审稿人进行。采用随机效应模型计算具有95%置信区间(CI)的CR合并患病率。研究间的异质性由I2确定。地理位置、收入水平、出版年份和样本量作为分组进行分析。结果:我们确定了2518项符合条件的研究,其中37项评估了10433名患者的CR患病率数据。CR的总患病率(PPr)为31.3% (95% CI: 0.22 ~ 0.40;i2 = 99.9%;p = 0.00)。2004 ~ 2023年CR发病率呈上升趋势,PPr值在7.4% ~ 50.6%之间。CR基因的分布存在差异,blaNDM是最常见的基因,其次是blaOXA和blaKPC。单因素荟萃回归分析显示,地理位置、收入水平、出版年份和样本量对异质性没有显著影响(P)。结论:结果表明,亚洲国家的CR监测对于减轻抗生素耐药性负担至关重要。减轻CR感染的影响将保障碳青霉烯类药物对后代的疗效,并减少CR基因的进一步传播。系统评价注册:PROSPERO CRD42024515806。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prevalence and molecular epidemiology of carbapenem resistance in Asia: a systematic review and meta-analysis.

Background: Carbapenems are a group of last-resort antibiotics used to treat serious life-threatening infections. The emergence of resistance to carbapenems is a major public health threat. However, comprehensive information on the prevalence and molecular epidemiology of carbapenem resistance (CR) among Asian countries is lacking. Therefore, we aimed to determine the prevalence of CR and associated molecular determinants quantitatively among Asian countries.

Methods: In this systematic review and meta-analysis, we searched published reports in electronic databases such as PubMed, ScienceDirect, the Cochrane Library, and Web of Science from 1st of January 2014 to 31st of January 2024 that fulfilled these criteria; original studies conducted in Asian countries including clinical isolates, and published in English. Data extraction and risk-of-bias assessment were performed by two independent reviewers. The pooled prevalence of CR with 95% confidence interval (CI) was computed with a random effects model. Heterogeneity across studies was determined by I2. The geographical location, income level, publication year, and sample size were analyzed as subgroups.

Results: We identified 2518 eligible studies, of which 37 assessed the CR prevalence data of 10,433 patients. The pooled prevalence (PPr) of CR was 31.3% (95% CI: 0.22 to 0.40; I2 = 99.9%; P = 0.00). A trend of CR incidence was observed from 2004 to 2023, with PPr values ranging from 7.4% to 50.6%. A variation in the distribution of CR genes was observed, with blaNDM being the most common gene, followed by blaOXA and blaKPC. Univariate meta-regression analysis indicated that geographical location, income level, publication year, and sample size did not significantly affect heterogeneity (P < 0.05).

Conclusion: The results suggest that surveillance of CR among Asian countries is essential to reduce the burden of antibiotic resistance. Mitigating the impact of CR infections will safeguard the efficacy of carbapenems for future generations and reduce further dissemination of CR genes.

Systematic review registration: PROSPERO CRD42024515806.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Systematic Reviews
Systematic Reviews Medicine-Medicine (miscellaneous)
CiteScore
8.30
自引率
0.00%
发文量
241
审稿时长
11 weeks
期刊介绍: Systematic Reviews encompasses all aspects of the design, conduct and reporting of systematic reviews. The journal publishes high quality systematic review products including systematic review protocols, systematic reviews related to a very broad definition of health, rapid reviews, updates of already completed systematic reviews, and methods research related to the science of systematic reviews, such as decision modelling. At this time Systematic Reviews does not accept reviews of in vitro studies. The journal also aims to ensure that the results of all well-conducted systematic reviews are published, regardless of their outcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信